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ORIGINAL ARTICLE
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ABSTRACT
Background: Oncokompas is a web-based self-management application that supports cancer survivors to
monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback
and tailored options for supportive care. In a large randomised controlled trial among survivors of head
and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved
to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small,
and no effect was observed on the primary outcome patient activation. Therefore, this study aims to
explore which subgroups of cancer survivors may especially benefit from Oncokompas.
Materials and methods: Cancer survivors (n¼ 625) were randomly assigned to the intervention group
(access to Oncokompas, n¼ 320) or control group (6months waiting list, n¼ 305). Outcome measures were
HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic
(sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treat-
ment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet
use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care,
measured at baseline. Linear mixed models were performed to investigate potential moderators.
Results: The intervention effect on HRQOL was the largest among cancer survivors with low to moderate
self-efficacy, and among those with high personal control and those with high health literacy scores.
Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the
mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms.
Discussion: Oncokompas seems most effective in reducing symptoms in head and neck cancer and
colorectal cancer survivors who report a higher burden of tumour-specific symptoms. Oncokompas
seems most effective in improving HRQOL in cancer survivors with lower self-efficacy, and in cancer
survivors with higher personal control, and higher health literacy.
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eHealth self-management interventions may have positive
effects on health-related quality of life (HRQOL) and symp-
tom burden among cancer survivors, but effect sizes vary
considerably [1–4]. It is likely that some cancer survivors may
benefit more from eHealth interventions than others, but
knowledge of possible moderators is scarce [5–8].
Oncokompas is a web-based self-management application
that supports cancer survivors to monitor their HRQOL and
cancer-generic and tumour-specific symptoms, and can be
used without help from a healthcare professional.
Oncokompas provides personalised feedback and informa-
tion based on scores from patient reported outcome meas-
ures (PROMs), and a tailored overview of supportive care
options. A tailored care approach is followed i.e.: in case of
minor problems information and self-help interventions are
proposed, and in case of major problems, professional care is
proposed [9,10].
In a previous paper we reported on the efficacy of
Oncokompas in a large randomised controlled trial (RCT)
among 625 cancer survivors. We showed that Oncokompas
had no significant effect on the primary outcome measure
patient activation (i.e., knowledge, skills, and confidence for
self-management) [11] in the total group, nor in tumour-spe-
cific subgroups of head and neck cancer, colorectal cancer,
breast cancer, or (non-)Hodgkin lymphoma [12]. However, a
significant beneficial effect was found on HRQOL in the total
group and several tumour-specific symptoms in survivors of
head and neck cancer, colorectal cancer, and non-Hodgkin
lymphoma [12]. Effect sizes on HRQOL were small (0.17–0.18)
and the effect sizes on symptoms that were significantly dif-
ferent varied from 0.18 to 0.80 up from 1week to 6months
follow-up [12].
Investigating the effect of potential moderating variables
is important to understand the generalizability of research
findings in subgroups [13,14]. However, moderating variables
of eHealth interventions are not often investigated. In previ-
ous RCTs and systematic reviews, several potential moderat-
ing factors were explored on the effect of psychosocial
interventions among cancer patients. A systematic review
showed that cancer patients with lower quality of life, inter-
personal relationships and sense of control benefitted more
from psychosocial interventions than those who already had
adequate resources [8]. An individual patient-data meta-ana-
lysis showed that psychosocial interventions significantly
improved HRQOL with small effect sizes after treatment,
while the intervention effects were larger among younger
patients [5].
Intervention effects are mostly in favour of those with a
higher education level, higher literacy, and those with higher
symptom burden or lower quality of life [5,15,16]. It is
expected that in eHealth interventions for cancer survivors
clinical factors such as tumour type and stage, type of cancer
treatment, and time since treatment, can moderate the effect
of the intervention, since symptoms and needs might differ
across these subgroups and decrease over time [17,18]. Also,
it could be expected that survivors with a higher need for
supportive care benefit more from interventions such
as Oncokompas.
The aim of this study was to investigate potential moder-
ating factors, including socio-demographic, clinical, and per-
sonal factors, HRQOL, symptoms, and need for supportive
care on the efficacy of Oncokompas on HRQOL, symptoms
and patient activation. For clinical practice, it is interesting to
know which subgroups of cancer survivors are most likely to
benefit from an eHealth self-management application such
as Oncokompas in terms of HRQOL and symptoms, and
patient activation. This knowledge can be used to further tai-
lor eHealth self-management interventions for optimal cancer
survivorship care.
Material and methods
Study design and population
This study entailed secondary analyses of a randomised con-
trolled trial (RCT) on the efficacy of Oncokompas compared
to usual cancer survivorship care. Detailed descriptions of
study procedures and primary results can be found else-
where [12,19]. In short, adult cancer survivors who were
treated with curative intent for head and neck cancer, colo-
rectal cancer, or breast cancer, or lymphoma (high- and low-
grade non-Hodgkin lymphoma, and Hodgkin lymphoma)
3months–5 years previously, were asked to participate in the
RCT by their (former) treating physician. Exclusion criteria
were: no access to the Internet or no email address, severe
cognitive impairment, insufficient mastery of the Dutch lan-
guage, physical inability to complete a questionnaire, and
breast cancer survivors with male sex. Survivors were
recruited from 14 hospitals in the Netherlands between 12
October 2016 and 24 May 2018. After providing written
(online) informed consent and completing the baseline
assessment, participants were randomised into the interven-
tion group (direct access to Oncokompas) or control group
(access to Oncokompas after a waiting period of 6months)
in a 1:1 allocation ratio, stratified per tumour type. Follow-up
assessments were 1-week post-intervention and at 3- and 6-
months follow-up. The study protocol was approved by the
Medical Ethics Committee of the VU University Medical
Centre (2015.523) and the trial was registered in the
Netherlands Trial Register (NTR5774).
Intervention
A detailed description of the intervention has been pub-
lished previously [12,19]. In short, Oncokompas is an eHealth
self-management application that supports cancer survivors
to monitor their HRQOL and cancer-generic and tumour-spe-
cific symptoms. The main goal is to obtain personalised feed-
back and information on their scores and a tailored overview
of supportive care options. Oncokompas includes various
topics in five generic HRQOL domains, which are relevant for
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survivors of all tumour types: physical, psychological and
social functioning, lifestyle, and existential issues, according
to the biopsychosocial model [20]. Besides, various tumour-
specific topics are addressed in tumour-specific modules tar-
geting head and neck cancer, colorectal cancer, breast cancer
and (non-)Hodgkin lymphoma survivors. Oncokompas con-
sists of three components: ‘Measure’, ‘Learn’, and ‘Act’. In the
‘Measure’ component, cancer survivors can complete PROMs
on the topic(s) of choice. Data from the ‘Measure’ compo-
nent are processed in real-time and linked to feedback in
the ‘Learn’ component. In the ‘Learn’ component feedback is
provided to the cancer survivor by means of a 3-colour sys-
tem: green (no elevated well-being risks), orange (elevated
well-being risks), and red (seriously elevated well-being risks).
Cancer survivors receive personalised information on the out-
comes, and comprehensive self-care advice. In the ‘Act’ com-
ponent, cancer survivors are provided with tailored
supportive care options, based on their PROM-scores and
expressed preferences (e.g., preference for individual therapy
versus group therapy). If a user has elevated well-being risks
(orange score), the feedback includes suggestions for self-
help interventions. If a user has seriously elevated well-being
risks, the feedback includes an advice to contact their med-
ical specialist or general practitioner [12,19,21].
Outcome measurement
Data on the outcome measures HRQOL, symptoms, and
patient activation were collected at time of inclusion (base-
line (T0)), 1-week post-intervention (T1), and after 3-months
(T2) and 6-months (T3) follow-up.
HRQOL was measured with the EORTC QLQ-C30 summary
score (SumSC). The SumSC is based on the five functional
scales (physical, cognitive, emotional, social, and role func-
tioning), three symptom scales (fatigue and nausea/vomiting,
and pain) and five single items (dyspnoea, insomnia, appetite
loss, constipation, diarrhoea) of the QLQ-C30. The SumSC
ranges from 0 to 100, with a higher score representing better
HRQOL [22].
Tumour-specific symptoms were measured with the
EORTC tumour-specific questionnaires. In the present study,
those subscales were used on which Oncokompas had a
beneficial effect in the RCT [5]: pain in the mouth, social eat-
ing, swallowing, coughing and trismus in head and neck can-
cer survivors (EORTC QLQ-H&N43) [23], weight in colorectal
cancer survivors (EORTC QLQ-CR29) [24], and emotional
impact in high grade non-Hodgkin lymphoma survivors
(EORTC-QLQ-NHL-HG29) [25]. All EORTC scales and single
items scores range from 0 to 100 (higher score indicating
higher burden of symptoms). Only these subscales were
chosen to limit the amount of analyses.
Patient activation was measured with the Patient
Activation Measure (PAM), which measures a patients’ level
of knowledge, skills and confidence for self-management.
The PAM score ranges from 0 to 100, with a higher score
indicating a higher level of patient activation [11].
Potential moderators
Potential moderators for the effect on HRQOL and patient
activation included socio-demographic, clinical and personal
characteristics, and patient activation, mental adjustment to
cancer, HRQOL, and need for supportive care, measured at
baseline. Potential moderators regarding symptoms included
socio-demographic and clinical characteristics, and the base-
line score of that symptom.
Socio-demographic characteristics included sex (male,
female), age (years), marital status (no partner, partner), edu-
cation level (low, medium, high), and employment status
(employed, not employed), and were measured with a study-
specific questionnaire.
Clinical characteristics included tumour type (head and
neck cancer, colorectal cancer, breast cancer, or lymphoma),
tumour stage (low stage (I or II), high stage (III or IV)), time
since diagnosis (categorised into 3–12months, 12–24months,
and 24–60months), treatment (none/single treatment, multi-
modal treatment), and comorbidities (none/one comorbidity,
two or more comorbidities). These characteristics were
retrieved from the Dutch Cancer Registry, or measured with
a study-specific questionnaire [19].
Personal factors included self-efficacy (General Self-Efficacy
(GSE) scale [26]), personal control (Pearlin and Schooler
Mastery (PSM) scale [27]), health literacy (Functional,
Communicative and Critical Health Literacy scale, summary
score [28]), health locus of control (Multidimensional Health
Locus of Control scale, with internal, powerful others, and
chance subscales [29]), and Internet use (<7 h per week,
>7 h per week).
Other potential moderators were patient activation
(Patient Activation Measure [11]), mental adjustment to can-
cer (Mental Adjustment to Cancer scale, with summary posi-
tive adjustment and summary negative adjustment subscales
[30]), HRQOL (EORTC QLQ-C30 summary score [28]), and
need for supportive care (Supportive Care Needs Survey 34-
items short form, with physical and daily living, psycho-
logical, sexuality, and health system, information and patient
support subscales, of which scores were dichotomised into
no unmet needs and unmet needs [31,32]). Tumour-specific
symptoms for head and neck, colorectal and high-grade
non-Hodgkin lymphoma were measured with the EORTC
tumour-specific questionnaires QLQ-H&N43, QLQ-CR29, and
QLQ-NHL-HG29, respectively [24,25,33].
Statistical analyses
Descriptive statistics were generated for sociodemographic
and clinical characteristics. Statistical analyses were per-
formed using the IBM SPSS Statistics version 26 (IBM Corp.,
Armonk, NY, USA).
To explore moderating factors on the efficacy of
Oncokompas compared to care as usual on HRQOL, symp-
toms and patient activation, from baseline to 6-months fol-
low-up, exploratory linear mixed model (LMM) analyses were
performed. The LMM included fixed effects for group (inter-
vention or control), time, their two-way interaction, the
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potential moderator, and the two- and three-way interactions
with group and time, and a random intercept for subject. A
significant three-way interaction effect (grouptimemodera-
tor) was considered as an indication of a difference in inter-
vention effect on the outcome, between (groups with)
different scores on the moderator. A p-value of <.05 was
considered to be statistically significant, and all analyses
were conducted according to the intention-to-treat principle.
To interpret the results of a dichotomous moderator vari-
able, post-hoc linear mixed-effect model analyses were per-
formed stratified for each subgroup of the moderator. To
interpret the results of a continuous moderator variable, esti-
mated marginal means were calculated for multiple values of
the moderator, and data visualisation was performed to
interpret the direction of the intervention effect.
Results
In total, 625 cancer survivors were randomised into the inter-
vention (n¼ 320) or control group (n¼ 305). Mean age was
63 years (standard deviation (sd) 11), 51% was female, 85%
had a partner, and 35% was employed at baseline (Table 1).
Furthermore, 30% was diagnosed with head and neck can-
cer, 24% with colorectal cancer, 24% with (non-)Hodgkin
lymphoma, and with 22% breast cancer. The median time
since diagnosis was of 27months (interquartile range (IQR)
1643). The baseline score of HRQOL (SumSC) was 85.4 (sd
14.3), and the baseline score of patient activation (PAM) was
59.3 (sd 12.5). Socio-demographic and clinical characteristics
of participants are summarised in Table 1. Details of the par-
ticipant flow and dropout have been published previ-
ously [12].
Regarding the effect of Oncokompas on HRQOL, self-effi-
cacy moderated this effect (measurementgroupself-effi-
cacy, F(3,1487)¼2.903, p¼ .034) (Table 2). Data visualisation
suggested that survivors with low GSE scores (low self-effi-
cacy) benefitted most from Oncokompas, whereas the inter-
vention effect became smaller when GSE scores were higher,
and the intervention effect almost disappeared in survivors
with high GSE scores (high self-efficacy) (Supplementary
Appendix Figure 1).
Personal control also moderated the effect of
Oncokompas on HRQOL (measurementgroup personal
control, F(3,1481)¼3.478, p¼ .015). Data visualisation sug-
gested that among survivors with low to moderate PSM
scores (lower sense of personal control), there was no inter-
vention effect, whereas survivors with high PSM scores (high
sense of personal control) benefitted most from
Oncokompas, via earlier improvement in HRQOL
(Supplementary Appendix Figure 2).
Also, health literacy moderated the effect of Oncokompas
on HRQOL (measurementgroup health literacy,
F(3,1478)¼2.869, p¼ .035). Data visualisation suggested that
there is no intervention effect among survivors with low to
Table 1. Baseline characteristics of participants.
Intervention (n¼ 320) Control (n¼ 305)
Socio-demographic factors
Age (mean, sd) 63.2 (11.2) 63.7 (10.1)
Sex (women) (n, %) 158 (49%) 158 (52%)
Education level (n, %)a
Low 111 (35%) 117 (38%)
Medium 105 (33%) 85 (28%)
High 103 (32%) 100 (33%)
Health literacy (mean, sd) 3.2 (0.5) 3.2 (0.5)
Marital status (partner) (n, %) 265 (83%) 269 (88%)
Employment status (employed) (n, %) 122 (38%) 99 (32%)
Clinical factors
Tumour type (n, %)
Breast cancer 66 (21%) 72 (24%)
Colorectal cancer 80 (25%) 72 (24%)
Head and neck cancer 99 (31%) 86 (28%)
Lymphoma 75 (23%) 75 (25%)
Tumour stage (n, %)
Stage I 106 (33%) 104 (34%)
Stage II 73 (23%) 70 (23%)
Stage III 61 (19%) 67 (22%)
Stage IV 64 (20%) 52 (17%)
Unknown 16 (5%) 12 (4%)
Treatment (n, %)
None/single treatment 137 (43%) 124 (41%)
Multimodal treatment 183 (57%) 181 (59%)
Comorbidities (n, %)
None/one comorbidity 249 (78%) 229 (75%)
Multiple comorbidities 71 (22%) 76 (25%)
Time since diagnosis (months, median, interquartile) range) 25.0 (16.0-41.0) 29.0 (16.5-41.0)
3–12months (n, %) 39 (12%) 38 (13%)
12–24months 104 (33%) 85 (28%)
24–60months 177 (55%) 182 (60%)
Personal factors
HRQOL (mean, sd) 85.3 (14.9) 85.4 (13.6)
Patient activation (mean, sd) 59.2 (12.5) 59.5 (12.6)
aEducation level was unknown for one participant in the intervention group, and three in the control group.
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moderate health literacy, whereas survivors with high health
literacy benefit most from Oncokompas, via earlier improve-
ment in HRQOL (Supplementary Appendix Figure 3).
Regarding the effect of Oncokompas on the investigated
symptoms, the baseline score of that tumour-specific symp-
toms moderated the effect (Table 3). Data visualisation sug-
gested that all survivors with some degree of symptom
burden at baseline benefitted from Oncokompas, and the
intervention effect became larger when the burden of symp-
toms was higher (e.g., pain in the mouth in Supplementary
Appendix Figure 4). In head and neck cancer survivors, this
was the case for pain in the mouth, social eating, swallowing,
coughing, and trismus. In colorectal cancer survivors, this
was the case for weight. Among non-Hodgkin lymphoma
survivors, the baseline score did not moderate the effect of
Oncokompas on emotional impacts. Furthermore, among
head and neck cancer survivors, Oncokompas was effective
to reduce pain in the mouth in women (F(3,154)¼5.107,
p¼ .002, but not in men (F(3,269)¼0.441, p¼ .72).
Oncokompas was effective to improve social eating in HNC
survivors without a partner (F(3,70)¼3.547, p¼ .019), but not
in those with a partner (F3,352)¼2.055, p¼ .11). Oncokompas
was effective to improve trismus in head and neck cancer
survivors without a partner (F(3,71)¼3.613, p¼ .017), but not
in those with a partner (F(3,354)¼0.797, p¼ .50). Age also
moderated the effect on trismus. Data visualisation sug-
gested that the intervention effect became larger with
increasing age.
Regarding patient activation, none of the investigated fac-
tors significantly moderated the effect of Oncokompas
(Table 2).
Discussion
This study aimed to explore which subgroups of cancer sur-
vivors may especially benefit from the eHealth self-manage-
ment application Oncokompas in terms of HRQOL,
symptoms, and patient activation. The effect of Oncokompas
Table 2. Potential moderators of the effect of Oncokompas on patient activation and HRQOL compared to care as usual.
HRQOL Patient activation
Potential moderator F (3,df) three-way interaction p value three-way interaction F (3,df) three-way interaction p value three-way interaction
Socio-demographic factors
Sex (men, women) 1.214 (1476) .30 0.036 (1414) .99
Age (years) 0.647 (1486) .59 0.442 (1430) .72
Marital status (no
partner, partner)
1.160 (1481) .32 0.591 (1417) .62
Education level (low,
medium, high)
1.699 (1457) .12 1.261 (1399) .27
Employment status (not
employed, employed)
1.468 (1478) .22 0.614 (1418) .61
Clinical factors
Tumour type (head and
neck, colorectal, breast
cancer, lymphoma)
1.780 (1465) .067 0.299 (1402) .98
Tumour stage (I or II vs. III
or IV)




1.633 (1473) .13 0.262 (1407) .95
Treatment (0/1,
2 treatments)
0.177 (1474) .91 0.576 (1417) .63
Comorbidities (0/1, 2
comorbidities)
0.960 (1478) .41 0.217 (1410) .88
Personal factors
Self-efficacy 2.903 (1487) .034 0.487 (1435) .69
Personal control 3.478 (1481) .015 1.620 (1431) .18
Health literacy 2.869 (1478) .035 0.847 (1434) .47
Health locus of control
Internal 0.736 (1475) .53 1.085 (1429) .35
Powerful others 1.359 (1476) .25 1.066 (1430) .36
Chance 0.762 (1481) .52 0.107 (1430) .96
Internet use (<7, >7 h/week) 1.960 (1470) .12 0.851 (1411) .47
Patient activation 2.124 (1353) .095 0.278 (1460) .84
Mental adjustment
to cancer
Positive adjustment 1.192 (1475) .31 0.498 (1428) .68
Negative adjustment 0.699 (1498) .55 0.540 (1442) .66
Unmet supportive
care needs
Physical and daily living 1.010 (1479) .39 0.756 (1413) .52
Psychological 0.237 (1479) .87 1.259 (1418) .29
Sexual 1.474 (1439) .22 0.376 (1372) .77
Health system, information
and patient support
0.228 (1478) .88 0.416 (1417) .74
HRQOL 0.903 (1617) .44 0.267 (1423) .85
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on HRQOL seems to last longer among cancer survivors with
low to moderate self-efficacy, survivors with higher personal
control, and those with higher health literacy. In reducing
symptoms, Oncokompas was more effective in head and
neck and colorectal cancer survivors with higher symptom
burden. Among head and neck cancer survivors,
Oncokompas was more effective in females (on pain in the
mouth), in survivors without a partner (on problems with
social eating and trismus), and in older survivors (on trismus).
With respect to patient activation, no specific subgroups
were found who might benefit more from Oncokompas
than others.
Although we aimed to develop a usable web-based appli-
cation suitable for many cancer survivors, by tailoring infor-
mation, limiting the amount of text, and making it accessible
for low-literate people, health literacy still was found to mod-
erate the effect of HRQOL, in favour of survivors with higher
health literacy. Health literacy is known to be an important
factor in eHealth interventions [34], and found to be posi-
tively associated with HRQOL [16,35,36]. Adaptations are
needed to improve the efficacy among those with lower
health literacy, for instance by adding multimedia compo-
nents, such as videos, podcasts, or infographics, or gamifica-
tion elements [37]. However, it might be that despite these
adaptations this group might benefit more from other types
of interventions, e.g., face-to-face or group interventions.
Interestingly, Oncokompas seems more effective in cancer
survivors with low to moderate self-efficacy. Self-efficacy is a
concept that influences how people think, feel, motivate
themselves, and act [38]. Our finding suggests that a low-
intensive intervention such as Oncokompas provides help or
tools to people with lower motivation or lower self-esteem
to act. Moderating effects of self-efficacy were also found
with an intervention on treatment information in breast can-
cer support groups; however, the effect on the outcome
emotional well-being was in favour of women with higher
self-efficacy [39]. On the other hand, the intervention effect
of a psychoeducational intervention for men with prostate
cancer has been shown in another study to be in favour of
those with lower levels of prostate-specific self-efficacy [40].
Furthermore, the intervention effect was also in favour of
those with high personal control. Personal control, or mastery,
refers to the degree to which controlling factors that influence
life situations can be perceived, and it has been found import-
ant for HRQOL and well-being [27,41]. The improvements in
HRQOL that were found in this group, suggest that fully-auto-
mated self-management interventions, can provide support to
those with high feelings of mastery, to enhance their sense of
mastery over their HRQOL and symptoms.
The intervention effect in favour of those with lower self-
efficacy and higher personal control seems to be contrary.
Examining the study population in the current study, persons
with lower self-efficacy were not the same persons as those
with higher personal control. It could be that cancer survi-
vors with lower self-efficacy need a push to take action, and
with Oncokompas, they have the tools to improve HRQOL.
The effect among cancer survivors with higher personal con-
trol might be because they feel in control with Oncokompas,
which leads to an earlier improvement in HRQOL. However,
because the interaction effects were small, it could be that
these findings were found by chance. Moderating effects of
mastery and self-efficacy on the effects of eHealth interven-
tions are not often investigated among cancer survivors.
Further research is needed to confirm whether the identified
moderating factors are moderating factors of eHealth inter-
ventions in general, or whether these factors especially mod-
erate the effect of fully-automated self-management
interventions.
Remarkably, baseline HRQOL did not moderate the effect
on HRQOL, but baseline symptoms did moderate the effect
on symptoms. This suggests that improvement of HRQOL is
possible for every cancer survivor, regardless of having a low
or high HRQOL at the start of the intervention, and the
benefit of Oncokompas might be through reducing symptom
burden. Evidence on moderating effects of baseline values of
HRQOL is inconsistent [5,42].
As we demonstrated previously, Oncokompas was not
effective in improving patient activation [12]. The current analy-
ses showed there are also no subgroups for which patient acti-
vation was improved, so it might be that there is truly no
effect of Oncokompas on survivors’ skills, knowledge and confi-
dence for self-management. This may be explained by the fact
that the study population comprises cancer survivors who had
access to the Internet, and who were doing relatively well in
terms of HRQOL, patient–physician interaction, adjustment to
cancer, and unmet supportive care needs. Another explanation
may be that most were long-term survivors (>2 years after
diagnosis), who might already found the information and sup-
port they need to build their skills and confidence to manage
cancer-related concerns [12,17]. Since the main aim of
Oncokompas is to improve HRQOL and reduce symptom bur-
den, we do not think that the content of Oncokompas should
be adapted towards an improvement of patient activation.
However, further research is needed to understand how cancer
survivors use Oncokompas, which topics are chosen, and how
usage and engagement can be improved. Further research is
also needed to confirm the moderating effects that were found,
and to enhance the understanding of how and under what cir-
cumstances eHealth interventions lead to beneficial effects.
The strengths of this study are the large sample size, with
participants from 14 hospitals across the Netherlands, and
that it includes various categories of moderators. However,
the results of this study should be considered with caution,
because of some limitations. This study was not powered to
detect differences in secondary outcomes, and to perform
secondary exploratory analyses to detect moderating factors.
Therefore, it is possible that important moderating factors
were not identified, because of a lack of power. Also, with
many potential moderators, and multiple outcome measures,
many separate models were analysed in the total group. As
a result, the observed effects might have been found by
chance. Because the analyses were only exploratory, and
there is no consensus on how to apply corrections for mul-
tiple testing [43], no corrections for multiple testing have
been made. In our previous publication, no effects were
found on other investigated secondary outcomes, such as
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self-efficacy and supportive care needs. It could be that these
outcomes are improved in specific subgroups of cancer survi-
vors, but we decided to limit the number of analyses by
focussing on HRQOL and symptoms, and the primary out-
come patient activation in this study.
This study provides valuable information on improving
the efficacy of future eHealth self-management interventions
targeting cancer survivors. Cancer survivors with low to mod-
erate self-efficacy, those with higher personal control, and
those with higher health literacy showed larger HRQOL bene-
fits of Oncokompas. Furthermore, Oncokompas is especially
effective to improve tumour-specific symptoms among survi-
vors of head and neck cancer and colorectal cancer with
higher symptom burden. Targeting these subgroups of survi-
vors might lead to improvements in the intervention effect
of eHealth self-management interventions.
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